NEW YORK, NY--(Marketwired - May 7, 2013) - Nuvilex, Inc. (OTCQB: [ NVLX ]) should be convincing investors by now that its technology could truly change the face of healthcare. Many know of the company's "Cell-in-a-Box" technology for its performance in clinical trials for advanced, inoperable pancreatic cancer, and its performance in pre-clinical studies for diabetes where it essentially created a type of "artificial pancreas." But, the company isn't stopping there when it comes to showing the technology's flexibility.

"Cell-in-a-Box" or living cell encapsulation has also been involved in treating mammary tumors in dogs. Mammary tumors in dogs are a "model system" that can be used to mimic breast cancer in humans. Clearly the company is demonstrating that it can encapsulate any type of living cell for use in the human body, and once transplanted into a patient, those cells will go to work to treat the disease or problem they're designed to treat. 

In the study to treat mammary tumors in dogs, as in the human pancreatic cancer studies, it emphasizes again that cell encapsulation can be used as a "targeting" device for the treatment of "solid" tumors. In the pancreatic cancer studies, Nuvilex's cell encapsulation was combined with the cancer killing drug ifosfamide; however, in the mammary tumors study, cyclophosphamide (Cytoxan) was used instead because cyclophosphamide is often used by veterinarians to treat canine mammary cancer and by oncologists to treat breast cancer in humans. 

The same type of drug-activating cells was encapsulated in the study as the company used for the pancreatic cancer studies because the same enzyme within those cells can activate both ifosfamide and cyclophosphamide. In the dog studies, encapsulated cells were injected into the mammary tumors and then followed by four treatments with cyclophosphamide.

To see how the company's cell encapsulation technology performed, continue reading this article at [ www.stockhousegroup.com/features ].

About Stock House Group
Stock House Group is a full service Investment Relations firm specializing in Awareness, Research, and Content Development. The firm offers a platform that allows CEOs to tell their story through the press with Feature Articles, Research Reports, and CEO Interviews. At the same time, Stock House Group is building a library of Research for Investors to use that allows them to get more informed on small cap stocks. For more information visit Stock House Group at [ www.stockhousegroup.com ].